{"id":46241,"date":"2022-07-15T16:02:00","date_gmt":"2022-07-15T14:02:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/"},"modified":"2022-07-15T16:02:00","modified_gmt":"2022-07-15T14:02:00","slug":"scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/","title":{"rendered":"Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect"},"content":{"rendered":"
\n

ALAMEDA, Calif.–(BUSINESS WIRE)–#CRISPR<\/a>–Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced its participation in the virtual Biopharma Private Company Connect event hosted by SVB Securities on July 20-21, 2022. Company executives, including CEO and co-founder Benjamin Oakes, PhD, and Chief Financial Officer David Parrot, will hold virtual one-on-one meetings with investors during the event. Meetings with the management team may be requested through SVB Securities.\n<\/p>\n

<\/a><\/p>\n

\nAbout Scribe Therapeutics<\/b>\n<\/p>\n

\nScribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company is backed by leading individual and institutional investors including Andreessen Horowitz, Avoro Ventures and Avoro Capital Advisors, OrbiMed Advisors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, and Menlo Ventures. To learn more about Scribe\u2019s mission to engineer the future of genetic medicine, visit www.scribetx.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nThermal for Scribe Therapeutics
\n
Kaustuva Das
\n
media@scribetx.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ALAMEDA, Calif.–(BUSINESS WIRE)–#CRISPR–Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced its participation in the virtual Biopharma Private Company Connect event hosted by SVB Securities on July 20-21, 2022. Company executives, including CEO and co-founder Benjamin Oakes, PhD, and Chief Financial Officer David Parrot, will hold … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46241","6":"format-standard","7":"category-industry"},"yoast_head":"\nScribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ALAMEDA, Calif.–(BUSINESS WIRE)–#CRISPR–Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced its participation in the virtual Biopharma Private Company Connect event hosted by SVB Securities on July 20-21, 2022. Company executives, including CEO and co-founder Benjamin Oakes, PhD, and Chief Financial Officer David Parrot, will hold ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-15T14:02:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220715005091\/en\/1514741\/21\/Scribe_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect\",\"datePublished\":\"2022-07-15T14:02:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\\\/\"},\"wordCount\":231,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005091\\\/en\\\/1514741\\\/21\\\/Scribe_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\\\/\",\"name\":\"Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005091\\\/en\\\/1514741\\\/21\\\/Scribe_Logo.jpg\",\"datePublished\":\"2022-07-15T14:02:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005091\\\/en\\\/1514741\\\/21\\\/Scribe_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005091\\\/en\\\/1514741\\\/21\\\/Scribe_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/","og_locale":"en_US","og_type":"article","og_title":"Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect - Pharma Trend","og_description":"ALAMEDA, Calif.–(BUSINESS WIRE)–#CRISPR–Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced its participation in the virtual Biopharma Private Company Connect event hosted by SVB Securities on July 20-21, 2022. Company executives, including CEO and co-founder Benjamin Oakes, PhD, and Chief Financial Officer David Parrot, will hold ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-15T14:02:00+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220715005091\/en\/1514741\/21\/Scribe_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect","datePublished":"2022-07-15T14:02:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/"},"wordCount":231,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220715005091\/en\/1514741\/21\/Scribe_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/","url":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/","name":"Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220715005091\/en\/1514741\/21\/Scribe_Logo.jpg","datePublished":"2022-07-15T14:02:00+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220715005091\/en\/1514741\/21\/Scribe_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220715005091\/en\/1514741\/21\/Scribe_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/scribe-therapeutics-to-participate-in-svb-securities-biopharma-private-company-connect\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46241"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46241\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}